scholarly journals Developing a scalable synthesis of Peloruside A

2021 ◽  
Author(s):  
◽  
Amira Brackovic

<p>Peloruside A (PelA, 1) is a marine natural product isolated from a sponge Mycale hentscheli found in Pelorus Sound, New Zealand. It is a microtubule-stabilising agent, active against various cancerous cell lines at nanomolar concentrations and offers several advantages over the current drugs on the market due to its unique mode of microtubule stabilisation, its potency and its activity in multidrug resistant cells. Since large-scale isolation of the compound from the sponge is unsustainable and an attempt to grow the sponge failed due to a sea-slug infestation, devising an efficient synthesis of peloruside A that will be able to deliver larger quantities of this compound is essential in order to conduct further studies and enable the eventual manufacture of the drug.   Peloruside A is also a very interesting synthetic target as a macrolide with ten stereogenic centres, an internal pyran ring and a trisubstituted Z-double bond. Our synthetic strategy combines elements from previous total and partial syntheses with novel elements with an aim to make the synthesis more efficient. The synthesis of the side-chain fragment (C12–C20) was based on Evans' methodology1 which was also utilised to couple this fragment with the C8–C11 fragments. It was envisioned to evaluate two different end-game strategies, and to this end it was necessary to synthesise two different versions of the C8–C11 fragment. However, the synthesis of the C1–C7 fragments proved to be quite challenging and required a lot of alterations to the synthetic plan and the protecting group strategy. Various routes based on previous syntheses by Ghosh, Jacobsen and Taylor were explored.2–4 Eventually, the key intermediate was synthesised using a modified Taylor methodology. Our future work will focus on optimising and establishing fragment coupling methodologies and evaluating the two end-game approaches: macrolactonisation and a ring-closing metathesis.</p>

2021 ◽  
Author(s):  
◽  
Amira Brackovic

<p>Peloruside A (PelA, 1) is a marine natural product isolated from a sponge Mycale hentscheli found in Pelorus Sound, New Zealand. It is a microtubule-stabilising agent, active against various cancerous cell lines at nanomolar concentrations and offers several advantages over the current drugs on the market due to its unique mode of microtubule stabilisation, its potency and its activity in multidrug resistant cells. Since large-scale isolation of the compound from the sponge is unsustainable and an attempt to grow the sponge failed due to a sea-slug infestation, devising an efficient synthesis of peloruside A that will be able to deliver larger quantities of this compound is essential in order to conduct further studies and enable the eventual manufacture of the drug.   Peloruside A is also a very interesting synthetic target as a macrolide with ten stereogenic centres, an internal pyran ring and a trisubstituted Z-double bond. Our synthetic strategy combines elements from previous total and partial syntheses with novel elements with an aim to make the synthesis more efficient. The synthesis of the side-chain fragment (C12–C20) was based on Evans' methodology1 which was also utilised to couple this fragment with the C8–C11 fragments. It was envisioned to evaluate two different end-game strategies, and to this end it was necessary to synthesise two different versions of the C8–C11 fragment. However, the synthesis of the C1–C7 fragments proved to be quite challenging and required a lot of alterations to the synthetic plan and the protecting group strategy. Various routes based on previous syntheses by Ghosh, Jacobsen and Taylor were explored.2–4 Eventually, the key intermediate was synthesised using a modified Taylor methodology. Our future work will focus on optimising and establishing fragment coupling methodologies and evaluating the two end-game approaches: macrolactonisation and a ring-closing metathesis.</p>


ChemInform ◽  
2004 ◽  
Vol 35 (24) ◽  
Author(s):  
Stuart J. Mickel ◽  
Gottfried H. Sedelmeier ◽  
Daniel Niederer ◽  
Robert Daeffler ◽  
Adnan Osmani ◽  
...  

2004 ◽  
Vol 8 (1) ◽  
pp. 92-100 ◽  
Author(s):  
Stuart J. Mickel ◽  
Gottfried H. Sedelmeier ◽  
Daniel Niederer ◽  
Robert Daeffler ◽  
Adnan Osmani ◽  
...  

2021 ◽  
Author(s):  
◽  
Febly Tho

<p>(+)-Peloruside A is a novel cytotoxic marine natural product isolated from the New Zealand sponge Mycale hentscheli(42). Peloruside A is a potential anticancer agent that has a similar mode of action to that of the successful drug paclitaxel. Biological analysis indicated that (+)-peloruside A promotes tubulin hyperassembly and cellular microtubule stabilisation which lead to mitosis blockage in the G2/M phase of the cell cycle and consequent cell apoptosis(43),(47). (-)-Laulimalide is also a cytotoxic natural product with microtubule stabilising bioactivity, and is a potential anticancer agent(47). Biological analysis showed that (+)-peloruside A and (-)-laulimalide are competitive, suggesting that they bind to the same active site(47). (+)-Peloruside A and (-)-laulimalide also display synergy with taxoids(47). Due to the structural complexity of peloruside A, our research has focused on developing an analogue 151 for ease of synthesis. Thus, the simplified C5-C9 dihydropyran moiety of (-)-laulimalide, with fewer stereocentres than that of (+)-peloruside A, has been incorporated into analogue 151 whilst retaining the 16- membered ring backbone of (+)-peloruside A. The proposed synthesis of 151 involves a Yamaguchi macrolactonization, a 1,5-anti-aldol coupling, and a ring closing metathesis as key reactions. This thesis reports on the synthesis of key fragments of analogue 151 and the crucial 1,5-anti-aldol coupling reaction for the assembly of the carbon backbone.</p>


2021 ◽  
Author(s):  
◽  
Febly Tho

<p>(+)-Peloruside A is a novel cytotoxic marine natural product isolated from the New Zealand sponge Mycale hentscheli(42). Peloruside A is a potential anticancer agent that has a similar mode of action to that of the successful drug paclitaxel. Biological analysis indicated that (+)-peloruside A promotes tubulin hyperassembly and cellular microtubule stabilisation which lead to mitosis blockage in the G2/M phase of the cell cycle and consequent cell apoptosis(43),(47). (-)-Laulimalide is also a cytotoxic natural product with microtubule stabilising bioactivity, and is a potential anticancer agent(47). Biological analysis showed that (+)-peloruside A and (-)-laulimalide are competitive, suggesting that they bind to the same active site(47). (+)-Peloruside A and (-)-laulimalide also display synergy with taxoids(47). Due to the structural complexity of peloruside A, our research has focused on developing an analogue 151 for ease of synthesis. Thus, the simplified C5-C9 dihydropyran moiety of (-)-laulimalide, with fewer stereocentres than that of (+)-peloruside A, has been incorporated into analogue 151 whilst retaining the 16- membered ring backbone of (+)-peloruside A. The proposed synthesis of 151 involves a Yamaguchi macrolactonization, a 1,5-anti-aldol coupling, and a ring closing metathesis as key reactions. This thesis reports on the synthesis of key fragments of analogue 151 and the crucial 1,5-anti-aldol coupling reaction for the assembly of the carbon backbone.</p>


Author(s):  
C. Nataraj

Abstract A single link robotic manipulator is modeled as a rotating flexible beam with a rigid mass at the tip and accurate energy expressions are derived. The resulting partial differential equations are solved using an approximate method of weighted residuals. From the solutions, coupling between axial and flexural deformations and the interactions with rigid body motions are rigorously analyzed. The emphasis in the current paper is not on an exhaustive analysis of existing systems but it is rather intended to compare and highlight the various flexibility effects in a relatively simple system. Hence, a nondimensional parametric analysis is performed to determine the effect of several parameters (including the rotating speed) on the errors and the individual interaction effects are discussed. Comparison with previous work in the field shows important phenomena often ignored or buried in large scale numerical analyses. Future work including application to multi-link robots is outlined.


2020 ◽  
Vol 6 (1) ◽  
pp. 5-12
Author(s):  
J.B. Zhang ◽  
J.K. Tomberlin ◽  
M.M. Cai ◽  
X.P. Xiao ◽  
L.Y. Zheng ◽  
...  

The larvae of the black soldier fly (BSF), Hermetia illucens L., are commonly associated with decaying organic wastes. Over the past 15 years, investigators in China have conducted extensive research exploring the use of BSF larvae to recycle organic materials as a means to protect the environment, while producing products of value, such as protein and bioenergy. Initial efforts were based on a BSF strain from the USA. However, since then, H. illucens strains from specimens collected in Hubei and Guangdong Provinces have been established and used as models to explore the use of this species in sustainable agriculture. China has played an instrumental role in developing an in-door breeding method using a quartz-iodine lamp rather than depend on natural sunlight. This discovery has allowed the establishment of in-door BSF colonies in regions throughout the world where abiotic conditions (i.e. cold temperatures) are preventative. Researchers in China paved the way for using microbes as a means to enhance BSF production including, enhancing BSF egg-laying as well as waste reduction. Furthermore, bacteria from BSF gut or waste can be cultured and used to promote BSF growth, shorten conversion time, and enhanced conversion efficacy. Recent efforts have demonstrated BSF larvae can degrade antibiotics as well as suppress noxious odours in livestock manure. Due to the efforts of research on BSF in China, numerous companies that recycle organic waste at a large scale (>20 tonnes waste digested/day), have been established. Resulting products include insect powder, and live BSFL that can be used as animal feed ingredients for livestock (e.g. eels and frogs), while protecting the environment. Future work will decipher the mechanisms regulating BSF larval conversion of organic waste so that the system can be optimised. However, efforts are still needed at the government level to establish quality assurance standards if this process is truly to become established as an industry in China.


2021 ◽  
Author(s):  
◽  
Oliver Bayley

<p>Cancer is currently the second largest cause of death globally, leading to a high demand for new and effective chemotherapeutics. For years, natural products have been used as a source of new bioactive compounds; of particular interest in this context, as a source of new chemotherapeutics. One chemotherapeutic candidate which has attracted significant attention in synthetic and medicinal chemistry communities, is peloruside A. Peloruside A is a bioactive secondary metabolite isolated from the New Zealand marine sponge Mycale hentscheli. Since its discovery, peloruside A has shown great promise in cancer studies both in vivo and in vitro with effects observed even at nanomolar concentrations. These chemotherapeutic effects have been shown to occur by halting cell division at the G2/M checkpoint via microtubule stabilisation. Of particular interest is that this stabilisation occurs in a manner distinct from that of the already established taxane class of microtubule stabilising drugs. This means that peloruside A is able to offer both inhibition of cell division in Taxol® resistant cells and synergistic inhibition alongside the current taxane drugs. Since peloruside A is not abundantly available from its natural source, there is a strong incentive for the development of new synthetic strategies for peloruside A production. Unfortunately attempts at aquaculture and attempts at developing an industrial scale synthesis have both proven unsuccessful thus far. In an attempt to overcome some of the difficulties with the scale up of peloruside, analogues have been developed that are intended to have similar bioactivity to peloruside A but simpler, more concise, synthetic routes. These analogues will also enable further elucidation of the binding properties of peloruside A. This project focuses on the generation of a functionalised pyran fragment, starting from a simple carbohydrate, that may be incorporated into the proposed analogues.</p>


Author(s):  
Maria José Saavedraa ◽  
João Carlos Sousa

Resumo A elevada mortalidade pelas doenças infecciosas, sobretudo epidémicas, mobilizou os cientistas na pesquisa de compostos naturais e produtos de síntese química dotados de propriedades antimicrobianas. Fazendo um pouco de história, referimos Paul Ehrlich, que utilizou o primeiro agente quimioterapêutico -Salvarsan, mais tarde Gerhard Domagk, que utilizou um pro-fármaco percursor de uma sulfamida. Em 1928, Alexander Fleming, descobriu de forma “casual” a penicilina, o primeiro antibiótico. Posteriormente em 1941 Howard Florey e Ernest Chain isolam e purificam a penicilina o que permitiu a sua utilização em larga escala -Era dos Antibióticos. A utilização dos antibióticos (AB) no tratamento das doenças infecciosas constituiu um dos maiores avanços da Medicina no séc. XX. No entanto a sua utilização em larga escala promoveu o aumento da incidência de estirpes multiresistentes aos AB, sobretudo em ambiente hospitalar. Adicionalmente verifica-se uma ocorrência cada vez mais elevada de estirpes resistentes na comunidade–humanos, animais e ambiente. O conhecimento dos mecanismos de ação e da ineficácia dos diferentes grupos farmacológicos de antibióticos é vital para o desenvolvimento de futuros microbianos, estando a ser estudados microrganismos do solo com a finalidade de encontrara novos fármacos. De realçar que a OMS preconiza que caminhamos rumo a uma "era pós-antibiótico”. Se não houver um plano de ação global para o "uso racional de antibióticos" a OMS prevê que em 2050 a resistência aos antibióticos, poderá matar mais de 10 milhões de pessoas.Palavras-chave: antibioterapia; resistência; antibióticos Abstract The current research on infectious diseases, especially with epidemic potential, has mobilized the scientific community to research on the natural substance and chemical probing products with antimicrobial properties. In a brief history of antibiotics, we refer to Paul Ehrlich, who used the first chemotherapeutic agent - Salvarsan, later Gerhard Domagk, who used a sulfamide precursor prodrug. In 1928 Alexander Fleming "casually" discovered penicillin, the first antibiotic. Later in 1941 Howard Florey and Ernest Chain isolate and purify penicillin that can be used on a large scale - Antibiotics Era. The use of antibiotics (AB) in the treatment of infectious diseases is one of the greatest advances of medicine in the 19th century. However, its large-scale use has increased the incidence of multidrug-resistant processes in AB, especially in a hospital setting. Besides, there is an increasing occurrence of resistant strains in different communities - humans, animals and in the environment. Understand the mechanisms of action and the ineffectiveness of the diverse pharmacological groups of antibiotics is crucial to provide further new antibiotic therapies in the near future. Recent studies have highlighted the soil-derived microorganisms as a novel approach to identify new drug substances. In this context, it is noteworthy that the World Health Organization (WHO) considers that we are moving towards a “post-antibiotic era”. If there is no global action plan for “rational use of antibiotics” WHO predicts that in 2050 the global impacts of antibiotic resistance on human heath will be catastrophic, killing more than 10 million people worldwide. Keywords: antibiotic therapy; resistence; antibiotics


Sign in / Sign up

Export Citation Format

Share Document